Inside EU Health Inside EU Health: EMA recommends five new medicines: Gilead HIV drug dispute; EU funds for innovative treatments; WHO extends PABS negotiations EMA recommends five new medicines for approval; MSF denied access to Gilead HIV-prevention drug; Europe invests €244 million to fast-track next-generation treatments for deadly infections; WHO members extend negotiations on pathogen sharing framework
EMA EMA recommends five new medicines addressing rare diseases and aggressive cancers The European Medicines Agency recommends five new therapies, including breakthrough treatments for small cell lung cancer and rare immune disorders, marking progress in areas of high unmet medical need
